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African trypanosomes are single-celled protozoan parasites that are capable of
long-term survival while living extracellularly in the bloodstream and tissues
of mammalian hosts. Prolonged infections are possible because trypanosomes
undergo antigenic variation—the expression of a large repertoire of antigen-
ically distinct surface coats, which allows the parasite population to evade
antibody-mediated elimination. The mechanisms by which antigen genes
become activated influence their order of expression, most likely by influen-
cing the frequency of productive antigen switching, which in turn is likely
to contribute to infection chronicity. Superimposed upon antigen switching
as a contributor to trypanosome infection dynamics is the density-dependent
production of cell-cycle arrested parasite transmission stages, which limit the
infection while ensuring parasite spread to new hosts via the bite of blood-
feeding tsetse flies. Neither antigen switching nor developmental progression
to transmission stages is driven by the host. However, the host can contribute
to the infection dynamic through the selection of distinct antigen types, the
influence of genetic susceptibility or trypanotolerance and the potential
influence of host-dependent effects on parasite virulence, development of
transmission stages and pathogenicity. In a zoonotic infection cycle where
trypanosomes circulate within a range of host animal populations, and in
some cases humans, there is considerable scope for a complex interplay
between parasite immune evasion, transmission potential and host factors to
govern the profile and outcome of infection.1. Introduction
African trypanosomes are protozoan parasites of a range of mammalian hosts,
infecting humans, livestock and wild animal reservoirs. Trypanosome infections
continue to have important consequences for health and economic prosper-
ity within afflicted regions [1,2] (figure 1a). The parasites are transmitted by
blood-feeding tsetse flies, where the parasite undergoes development and non-
obligatory sexual exchange [3] prior to inoculation into a new mammalian host
in the saliva of the infected fly. Unusually for blood-borne protozoan parasites,
trypanosomes exist extracellularly throughout their life cycle, meaning that not
only must they resist innate immune responses but they must also overcome con-
tinual exposure to the humoural immune responses of their mammalian hosts.
Thwarting adaptive host immunity allows trypanosomes to survive and establish
chronic infections, enhancing transmission and dissemination. They achieve this
through an extreme capacity for antigenic variation, allowing the parasite popu-
lation to evade host antibody responses for months to years (figure 1b). The
molecular mechanisms of trypanosome antigenic variation have been the subject
of intense research for over three decades and are the subject of several recent
reviews [4–7]. In recent years, however, the sophistication of the parasite’s
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T. b. gambiense: 
24 countries in West and central Africa. Responsible for 98% of cases. 
This is a chronic disease that progresses over months–years. 
T. b. rhodesiense: 
three countries in eastern and southern Africa. Responsible for 2% of cases.
This is an acute disease that progresses over weeks–months. 
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Figure 1. An overview of African trypanosomiaisis. (a) Shows a summary of the distribution and disease profile of the two species of African trypanosome responsible for
human infection. Animal African trypanosomiasis (caused by T. brucei, T. congolense and T. vivax) is distributed throughout sub-Saharan Africa coincident with the dis-
tribution of the disease vector, tsetse flies. (b) Shows the conventional view of a trypanosome infection profile. Infection chronicity is achieved by appearance of a
progression of waves of parasitaemia with distinct waves being composed of trypanosomes with antigenically distinct coats (for simplicity, each wave is shown as a
single VSG, though normally many VSGs are represented per wave). Within each wave of parasitaemia, a developmental switch occurs, whereby proliferative slender
forms become arrested stumpy forms as parasite numbers increase in response to the accumulation of the quorum-sensing signal, SIF.
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2strategies to achieve infection chronicity, and so increase their
capacity for transmission, have become clear, revealing a com-
plex interplay between the parasite’s strategies for immune
evasion, their developmental control of transmission potential
and the contributions of host immunity in a field setting where
hosts can be continually exposed to trypanosome infections
[8–12]. The interactions between these different parasite and
host components of the infection dynamic are likely to drive
responses that shape the epidemiology and evolution of the
infection over time and in different geographical settings.
This review seeks to summarize how the different contributors
to the trypanosome infection profile operate and interface to
create a complex and finely balanced host–parasite interaction.2. Antigenic variation
In themammalian bloodstream, the surface of theAfrican tryp-
anosome cell is completely enshrouded by a homogeneous
protein coat comprising a single variant surface glycoprotein
(VSG) type [13]. The VSG is a glycophosphatidylinositol-
anchored glycosylated protein that shields common and invari-
ant antigens on the parasite surface from the immune system
[4] and protects the parasite from complement activated by
the alternative pathway [14]. Although the key component
of the parasites’ immune evasion strategy, the VSG is highly
immunogenic. Specifically, an antibody response is raised to
epitopes on the exposedN-terminal domain of the VSG, result-
ing in parasite lysis by the classical pathway of complement
activation [15]. This, however, does not clear the infection as
a proportion of parasites switch to the expression of an antigen-
ically distinct VSG, which is not recognized by antibodies
raised to earlier antigen types. Experimentally, at least 100
antigenically distinct coats have been observed to be expressed
from a single infecting trypanosome [16], but this isundoubtedly an underestimation due to detection limitations.
In reality, the trypanosome’s potential for the expression of
distinct antigenic types may be almost limitless, due to the
possession of a huge archive of VSG genes and highly flexible
‘switching’ mechanisms that allow new VSGs to be activated
during antigenic variation.
The expression of a given VSG gene depends upon its
location within an active telomeric VSG expression site, of
which there are potentially 15–25 in the trypanosome
genome [17,18], eachwith a different VSG. Only one expression
site is fully active at a time [19], this being uniquely associ-
ated with a sub-nuclear transcription factory, the expression
site body [20,21]. In addition, a complex interplay between epi-
genetic silencing factors [22], telomere factors and nuclear
envelope association act to ensure allelic exclusion and inactiv-
ity of the other expression sites [5]. Active expression sites are
transcribed by RNA polymerase I [23] and several expression
site-associated genes (ESAGs) are co-expressed with the VSG
gene in the same polycistronic transcription unit [24–26]. The
multiplicity of VSG expression sites means that expression of
a new VSG gene can occur through a transcriptional switch
that activates a new expression site and silences the previously
active site. However, by far themost common route of VSG coat
switching involves recombination (approx. 90% of switching
events [27]), mainly through gene conversion events in which
a silent VSG gene is copied and replaces the expressed VSG
in the expression site. It is this type of VSG switching that
allows prolonged infections and generates VSG diversity
beyond the number of VSG genes in the genome archive.
The scale of the archive of VSG genes in trypanosomes is
huge, dwarfing the number of antigenically variant genes
in the genomes of other organisms, such as Plasmodium,
that also rely on antigenic variation for survival. The VSG
repertoire has been characterized in two strains of Trypanosoma
brucei [28–30], where antigenic variation is best described, as
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Figure 2. VSG gene conversion during antigenic variation. (a) Gene conversion of intact VSG genes into the active bloodstream VSG expression site (BES), using
donor VSGs that are either present in a minichromosome or a subtelomeric VSG array. In all cases, the VSGs are shown as coloured arrows and the extent of
sequence copied during gene conversion is indicated by a grey box, within which the direction of copying is shown by a white arrow. During gene conversion
from a silent minichromosome or array VSG (both light blue), the upstream boundary is normally 70 bp repeats (hatched box), which are found adjacent to most
VSGs (though their numbers are lower when associated with array VSGs). The downstream boundary of gene conversion is frequently the 30 end or 30 flank of the
VSG, though this can extend further when minichromosome VSGs act as donors, including reactions that encompass the telomere repeats (small, arrayed arrows). In
the BES, ESAG genes (white arrows) are co-transcribed with the VSG (red) from a common promoter (thin black arrow); silent BES (not shown) can also act as donors
of new VSGs by gene conversion, or can elicit VSG coat changes by transcriptional switching (not shown; see text). (b) Segmental gene conversion to form novel
mosaic VSGs. In this reaction, multiple silent VSGs (here, three: light blue, orange and green) are recombined together to form a new VSG that is a composite of the
three gene sequences. The VSGs that act as donors in segmental gene conversion are frequently pseudogenes and are normally located in disparate regions of the
subtelomeric array archive. Many details of this reaction are uncertain, and some assumptions or simplifications are made: segmental gene conversion to form VSG
mosaics may not happen in the active BES, as shown here; gene conversion is shown to encompass only VSG ORF-internal sequences, but the reactions may be
‘anchored’ by upstream or downstream homology; VSG mosaics normally display much greater intermingling of the donor VSG sequences than is indicated here.
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3well as in the animal infective trypanosomes Trypanosoma vivax
and Trypanosoma congolense [31]. Even though the VSG catalo-
guing is still incomplete, the T. brucei genome can contain more
than 2000VSGgenes (more than 20%of the coding genome), of
which themajority exist in transcriptionally silent subtelomeric
arrays, although a substantial fraction are found in aneuploid
minichromosomes. The VSG repertoire appears highly
dynamic, with changes in VSG numbers and identities detect-
able during strain propagation [30], and larger scale
rearrangements leading to chromosome size variation within
and between strains [32]. Most VSGs are single copy in the
archive, sharing little primary sequence homology with other
VSGs. However, only approximately 5–10% of the subtelo-
meric array VSG repertoire encodes intact and functional
VSGs, with the remainder either containing frameshifts or
truncations rendering them incapable of generating intact
VSGs (approx. 80–85%) or encoding predicted features that
are atypical of VSGs (10%) [33]. Importantly, the VSG pseudo-
genes are not non-functional, but make a major contribution to
antigenic variation (see below). Nonetheless, the detection of
such a large pseudogenic repertoire was unexpected, particu-
larly as other organisms (e.g. Anaplasma marginale andBorrelia burgdorferi) that use similar gene conversion strategies
based on antigen pseudogenes can generate antigenic variation
and chronic infections with much smaller gene repertoires
(tens of genes) [7]. Moreover, until genome sequencing, the
activation of new VSGs based on pseudogenes, though
detected [34,35], was thought to be a rare event during tryp-
anosome infections; in fact, it appears to be the major driver
of long-term infections and transmission [36–38].
Two different gene conversion reactions contribute to
VSG switching (figure 2). In one reaction, an intact, pre-
viously silent VSG replaces the complete VSG in the active
expression site (figure 2a). This reaction is dependent upon
flanking sequence homology, perhaps most notably
upstream 70 bp repeats that are uniquely associated with
approximately 90% of VSGs [37]. The 70 bp repeats delimit
the boundary of VSG gene conversion of intact VSGs
from the subtelomeric arrays and the minichromosomes.
VSGs in the silent expression sites also act as substrates in
intact VSG gene conversion and, despite the greater available
homology, the increased numbers of 70 bp repeats in these
sites mean they are also frequently, though not exclusively,
the upstream boundary here [39–41]. The second reaction,
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4termed segmental gene conversion, involves recombination
driven by the coding sequence of the VSGs, so enabling util-
ization of the VSG pseudogenes; here, multiple VSG ORFs
(intact, pseudogene or gene fragments) can be recombined
(figure 2b), creating novel antigens (mosaic VSGs) and there-
fore multiplying the potential expressed VSG diversity well
beyond the limitations of the existing genome’s VSG reper-
toire [37,38]. We have much to learn about this reaction; for
instance, unlike VSG conversion of intact genes, which gen-
etic evidence shows is linked to homologous recombination,
no factors (cis- or trans-acting) that act in segmental VSG
gene conversion have been described; also, we do not know
where VSG assembly occurs in the genome.
The different mechanisms of VSG gene activation
(expression site activation, gene conversion driven by flanking
repeat sequences, assembly of mosaic genes) have different
probabilities that shape the profile of expressed VSGs during
a chronic infection [42]. Early in infection, switching between
intact telomeric VSG genes seems to predominate. In part,
this may be due to transcriptional switching, perhaps as
a means to establish active transcription of the most host-
appropriate expression site [43]. However, it is also a result of
early telomeric VSG recombination, which may reflect the
observation that the proportion of such VSGs that are intact
and functional, both in the expression sites [18] and in themini-
chromosomes [30], is much higher than in the subtelomeric
arrays. Equally, telomeric location may promote recombino-
genic interactions [44]. Activation of intact silent subtelomeric
VSG genes by gene conversion using homologous flanking
sequences is seen next; because these events are independent
of the sequence of the previously expressed VSG, the order
of VSG activation is unpredictable. Thereafter, mosaic VSG
assembly by segmental gene conversion predominates and
sustains the appearance of new antigen types [37,38], this
being necessary to maintain the infection in a context where
parasites expressing or re-expressing frequently activated
VSG are eliminated by antibodies generated during exposure
earlier in the infection. In this phase of the infection, recombin-
ation within the coding region of VSG genes appears to
generate dependency on the previously expressed VSG gene,
based on a requirement for relatively closely related VSGs,
creating the potential for directionality in the order of activa-
tion of VSG genes. Although this has the potential to create a
further hierarchy in the appearance of expressed antigens, the
complexityof the recombination events and the selection of anti-
genically novel VSG assemblies by the immune system makes
the expressed VSG unpredictable and the available evidence
suggests increasing VSG diversity with time [38]; indeed, it is
probable that the capacity for such diversity has been signifi-
cantly underestimated by the experimental approaches used
to date. Moreover, as the assembly of VSG mosaics initiates
and progresses independently in each infection, different hosts
will be exposed to completely different antigen repertoires
that would prevent any possibility of generating meaningful
immunity to the infecting parasite population or to subsequent
co-infecting trypanosome populations.3. Developmental contributions to the infection
dynamic
Like many pathogens, the trypanosome must balance viru-
lence (defined here as proliferation in the host), pathogenicity(defined here as damage to the host) and transmission (i.e.
the capacity for its successful uptake and establishment in
the tsetse fly) to maximize its long-term survival and spread.
The trypanosome achieves this by regulating its growth
within mammalian hosts in a density-dependent manner
[45–47] and through the generation of a specialized develop-
mental stage, the stumpy form, optimized for transmission to
tsetse flies [48]. These adaptations are linked because the
stumpy forms are non-proliferative and are generated from
proliferative slender forms through a quorum-sensing-like
process, whereby a soluble parasite-derived factor triggers
the developmental transition [45]. The identity of the factor,
called stumpy induction factor (SIF) (though it may in fact rep-
resent a mixture of factors), is unknown but evidence suggests
that it is small (less than 500 Da), heat stable and generated by
slender forms, such that it accumulates to provide a measure of
parasite density [45]. While the factor is uncharacterized, a
recent genome-wide screen identified molecular components
of the cellular response pathway leading to the production of
stumpy forms [49]. Several protein kinases and phosphatases
were revealed as signal transduction components, as well as
gene expression regulators (namely predicted RNA-binding
proteins) and hypothetical proteins of unknown function.
The screen identified drivers of stumpy formation whose
genetic depletion or ablation prevented the developmen-
tal response regardless of parasite density, complementing
earlier studies that had identified molecules able to inhibit
stumpy formation [50–52]. Analysis of the identified pathway
components has shown similarity to nutrient sensing and
developmental responses in yeasts and Dictyostelium [49,53],
suggesting that the signalling pathways regulating trypano-
some stumpy formation share evolutionary origins with
fundamental environmental sensing pathways conserved in
diverse eukaryotes [53].
The balance between slender and stumpy forms within
each wave of parasitaemia and during the course of a chronic
trypanosome infection plays a significant part in controlling
the infection dynamic of the parasite [8]. Early in infection,
the parasites are predominantly slender and numbers rapidly
increase [9]. However, the accumulation of SIF drives cell-
cycle arrest and then morphological development to stumpy
forms, this being accompanied by the expression of several
stumpy form characteristics, including the expression of the
PAD1 surface transporter that detects transmission of the para-
sites taken up in a tsetse fly blood meal [54]. Stumpy forms are
also somewhat more robust than slender forms: they are more
tolerant of pH stress and proteolytic attack [55] (aiding their
survival in the tsetse midgut) and are better able to survive
at equivalent antibody titres [56,57], this being assisted by
their capacity for the clearance of antibody from their surface
by hydrodynamic flow [57].
Nonetheless, with sufficient antibody titres, both slender
and stumpy forms are destroyed such that the parasite numbers
rapidly decline. Despite its stability in vitro, SIF must rapidly
turn over in vivo, allowing parasites that have undergone an
antigenic switch to begin to accumulate as proliferating slender
forms and thereby re-establish the parasitaemia. In textbook
descriptions, this balance between proliferation as slender
forms, differentiation to stumpy forms, the immune clearance
of slender and stumpy forms and the recrudescence of anti-
genically distinct slender forms generates regularly periodic
waves of parasitaemia. However, a quantitative analysis of
parasite numbers and the proportion of stumpy forms in
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Figure 3. The classical description of the interplay between antigenic variation and infection chronicity (redrawn from [58]). In scenario A, the parasites overgrow
and kill the host. Scenario B occurs when parasites are rapidly cleared from the host. Scenario C is characteristic of trypanosome infections and is dependent upon
both antigenic variation to evade specific immune responses (prevents scenario B) and density-dependent differentiation of slender to stumpy parasites (prevents
scenario A). These processes are parasite-driven and independent of the host. Scenario C maximizes transmission, which will ultimately be the primary selective force
on the trypanosome population. Several factors will determine the kinetics of infection in scenario C (i.e. infection duration and total parasite load; D) and these will
include host susceptibility, parasite virulence and population factors such as herd immunity and co-infections, and the interplay of these factors with parasite
antigenic variation and differentiation. These selective factors will shape the usage and evolution of the VSG repertoire at the individual and population levels.
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5chronic mouse infections demonstrated a more complex infec-
tion profile, where distinct cyclical waves of parasitaemia
were not obvious later in infection and stumpy forms stably
predominated in the overall parasite population [9]. This infec-
tion profile has been interpreted to help the trypanosomes
to get an early foothold in a mammalian infection, aided by
the proliferation and rapid antigen switching of the initial
slender population, with the later stumpy-enriched popula-
tion in a chronic infection prolonging host survival and
enhancing the probability of transmission [8]. Thismodel, how-
ever, has not been tested in livestock infections where
parasitaemias are usually lower than in mice, and in which
the textbook infection kinetics of distinct peaks of parasitaemia
are more readily identified.4. Balancing virulence and transmission in
trypanosome infections
The development of stumpy forms might serve several
beneficial purposes for trypanosomes (figure 3). Firstly, the
production of arrested stumpy forms as the parasitaemia
accumulates prevents an uncontrolled proliferation of slender
forms that would rapidly kill the host. Secondly, the more
robust nature of the stumpy form when compared with the
slender form would promote its survival upon transmission
to the tsetse fly, where the parasite is attacked by the proteo-
lytic environment of the insect midgut. Finally, by reducing
the overall proportion of proliferative forms in the mamma-
lian parasitaemia in chronic infections, the overall frequency
of antigenic variation would be reduced [9] (as only prolifera-
tive forms would undergo productive antigen switches),
potentially prolonging the functional within-infection life-
time of the antigen repertoire [9], and this limitation on
repertoire usage may also play a role in restricting herd
immunity and reinfection at the host population level [8].
Although each of these potential benefits would apparently
favour parasite survival and spread, direct evidence foreach is limited. For example, while the laboratory selection
of parasite lines that can no longer generate stumpy forms
does generate virulent lines that rapidly kill the host
[59,60], stumpy forms are not detected in other African tryp-
anosome species outwith the T. brucei group (e.g. T. congolense
and T. vivax) [61,62]. These species nonetheless are sustained
successfully in sub-Saharan Africa and transmitted by tsetse
flies, with T. congolense entering the fly midgut initially to
establish infection. Furthermore, there is little experimental
evidence that the proportion of stumpy forms in an infection
dominates the likelihood of transmission. While studies
clearly support the importance of stumpy forms in trans-
mission [63], the advantage of having 90% as opposed to
10% stumpy forms in a tsetse blood meal is less clear assum-
ing sufficient parasites are ingested. Finally, the significance
of restricting exposure to the immune system of different anti-
gen types is unknown. While the rapid expression of many
antigen types might unnecessarily expose the parasite’s
VSG repertoire and so limit infection chronicity, the simul-
taneous expression of many diverse antigen types might
also restrict the production of an effective immune response
against any one antigen type [10,64]. This might allow minor
types to sustain expression or to be re-expressed later in
infection when dominant antigen types are eliminated. Fur-
thermore, the simultaneous expression of many different
antigen types in the infection could act to perturb immune effi-
cacy or promote immunosuppression. Following the recent
ability unambiguously to identify stumpy forms in an infection
using PAD1 as a molecular marker [9], the capacity to identify
expressed antigen genes at the population level by deep
sequence expression analysis and the tools to activate or inhibit
stumpy formation via RNAi or gene overexpression [49],
the contributions to each of the different components of
the trypanosome infection dynamic are now accessible to
experimentation. This places us in an excellent position
to understand how trypanosomes contribute to their parasitae-
mia and the consequences of perturbing different components
in the context of acute and chronic infections.
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65. Contributions from the host
Unusually in pathogen biology, trypanosome research has
placed relatively little emphasis on the analysis of host contri-
butions to the context of infection. Largely, this has been
because antigenic variation and development in the host are
parasite-intrinsic factors. Nonetheless, while the humoral
response is clearly necessary to control each variant antigen-
expressing subpopulation, host contributions to parasite viru-
lence and the infection dynamic can be complex and host
species dependent, limiting experimental tractability outwith
themousemodel of infection. For example, populations of live-
stock and game animals continually exposed to trypanosome
infections over time may have the capacity to develop herd
immunity, restricting the ability of the circulating parasite
population to be transmitted to, and establish in, new hosts
[33]. Here, the development of unique antigenic lineages
derived from sequential mosaic formation over the course of
a chronic infection might play a key role in enabling the para-
site to establish in previously or currently infected hosts
[12,65]. Similarly, the rapid antigen switching characteristic
of field strains of parasites [66] (as occurs early in infections
enriched in slender forms) might allow the parasite to probe
the immune status of the host until a sufficiently novel antigen
type is expressed, allowing the parasite to establish [8]. The
diversity and flexibility of the metacyclic VSG repertoire
(the VSG expressed from a specialized subset of expression
sites activated in the tsetse fly salivary gland in the life cycle
stage pre-adapted for mammalian host infection) will also pro-
vide increased capacity to infect previously exposed hosts
exhibiting herd immunity [67,68]. The metacyclic VSG reper-
toire is somewhat isolated from the VSG repertoire used in
established bloodstream infections, with M-VSG expression
sites being shorter, generally lacking in ESAGs and with
few or no flanking repeats, limiting their recombination
with bloodstream expression sites. Although of more limited
diversity (there are around 12–20 M-VSG types [68,69]), the
short-term expression of these may limit their immune stimu-
lation, helping the parasite to establish and proliferate until it
can switch to expression of antigens from the much larger
bloodstream repertoire.
Beyond immunity, there is evidence that the control of tryp-
anosome infections has a strong host component. The most
obvious example of this interaction is the inability of most Afri-
can trypanosomes (including Trypanosoma brucei brucei,
T. congolense and T. vivax) to infect human and primate hosts
through the presence and expression in humans and primates
of trypanolytic serum factors, TLF1 and TLF2, each containing
the lytic ApoL1 component of high-density lipoprotein
[70]. Trypanosoma brucei rhodesiense and Trypanosoma brucei
gambiense have both evolved independent mechanisms to
evade killing in human serum through their expression of SRA
[71] and TgsGP1 [72,73], respectively, with a downregulation
of the haptoglobin–haemoglobin receptor also contributing to
T. b. gambiense resistance. Counter selection in some human
populations for mutations in ApoL1 generating a form able to
killT. b. rhodesienseprovides evidenceof theevolutionary conflict
between humans and trypanosomes, with the trade-off in this
case being an increased risk of kidney disease [70,74].
Aside from the binary trait of human infectivity, there is
evidence for a genetic basis underlying factors that determine
the kinetics and duration of infection, in both parasite and
host populations. In mammalian hosts, there is a spectrum ofinherent susceptibility to trypanosome infections, ranging
from fully susceptible hosts that succumb and die after a short
infection timecourse to those defined as ‘trypanotolerant’, or
hosts that remain infected but do not develop the severe clinical
signs of their susceptible counterparts. At a population level,
the variation in these host factors will have a clear influence
on parasite transmission, as well as the usage and evolution
ofVSG repertoires. Animalmodels of the trypanotolerancephe-
notype have long been recognized and are particularly well
defined in mice and cattle with respect to T. congolense infec-
tions, but the variation in infection outcome phenotype has
also recently been identified in human patients infected with
T. b. gambiense [75,76], with an infection status analogous to
trypanotolerance being characterized [77]. Indeed, genes, alleles
and pathways have been identified that are suggested to
contribute to host susceptibility in mice, cattle and humans
[75,76,78], although it is clear that the phenotype is a quantita-
tive trait in all species with contributions from multiple genes,
many of which remain to be identified.
The influence of parasite genotype on infection severity and
outcome is also profound, with some strains generating acute
and severe infections and others chronic infections with mild
symptoms—the classic example being infections in humans
with T. b. gambiense tending to be more chronic, whereas
T. b. rhodesiense infections are often very acute. Phenotypes relat-
ing to infection severity have been shown to be heritable in the
T. brucei model in mice, and similar to trypanotolerance in
the mammalian host these are quantitative traits with multiple
genes involved [79,80]. Therefore, it is clear that the interplay
between genes and pathways involved in host susceptibility
and trypanosome virulence will have a significant impact
upon the kinetics of infection, including parasitaemia, infection
profile and infectionduration, all ofwhichwill interactwith anti-
genic variation and differentiation to shape the within-host
dynamics of infection and onwards transmission.6. The impact of co-infections and zoonosis
on trypanosome infection dynamics
African trypanosomes have the capacity to infect a wide range
of mammalian hosts (figure 4a). While T. b. rhodesiense and
T. b. gambiense can infect humans, these species also have
animal reservoirs, including livestock and game animals, that
can probably sustain the parasites in an infection cycle long-
term without human involvement. Similarly, with a relatively
high frequency of trypanosome infection in animal reservoirs
combined with the typically chronic nature of trypanosome
infections, the probability of mixed infections between dif-
ferent genotypes or species is significant [81]. This likely
generates the potential for evolutionary conflict, particularly
in the context of an operating quorum-sensing system. Thus,
if two different parasite genotypes exchange density sensing
signals, there is the theoretical possibility for selection to
occur, whereby the parasites either exploit or perturb each
other’s signals for their own advantage. This has the potential
to select parasites less able to respond to a density sensing
signal such that they come to dominate in a mixed infection,
or, hypothetically, to even produce a SIF mimic which prefer-
entially limits the proliferation of a competing strain without
affecting the producer strain. This conflict could operate to
increase the virulence of parasites when competing in a pool
of hosts where the parasites are circulating so that they sustain
(i)(b)(a)
trypanosome species
T. b. gambiense
T. b. rhodesiense
T. b. brucei
T. congolense
T. vivax
host range
(ii) (iii)
Figure 4. Possible conflicts driving parasite virulence in different host settings. (a) The host range of different trypanosome species is shown, with T. b gambiense
and T. b. rhodesiense being human infective. Trypanosoma brucei gambiense can also infect livestock, though human infection is more frequently detected;
T. b. rhodesiense is most frequently found in livestock and game animals. Trypanosoma brucei brucei, T. congolense and T. vivax cannot infect humans but are
maintained in game animals and livestock. (b) Three scenarios where parasites are transmitted either to trypanotolerant or susceptible hosts, or humans. In
each scenario, potential outcomes are: (i) in trypanotolerant hosts, host suppression selects for increased virulence of the parasite population; (ii) parasites
might exhibit increased virulence once released from either host suppression in susceptible animals or competition from co-infecting strains; and (iii) in
humans, T. b. rhodesiense or T. b. gambiense are released from inter-species competition and may exhibit increased virulence.
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If removed from the competitive environment—for example,
by infecting a new uninfected host, transitioning from a tryp-
anotolerant to a more susceptible host or moving from an
animal host to a human host (in the case of T. b. gambiense or
T. b. rhodesiense)—the consequence could be the appearance
of highly virulent forms that are more pathogenic to the host
(figure 4b). The associated trade-off is, potentially, reduced
capacity for transmission through their reduced production
of stumpy forms in that host [8], but the pivot point when
increased virulence and decreased transmission and vice versa
become strongly deleterious is unknown. Nonetheless, a con-
flict between virulence and transmission is inevitable either
with single or mixed infections, and variable between different
hosts, and there is considerable scope for the evolution of sys-
tems that provide misinformation to competitors. The extent of
the importance or stability of such selection pressures is
unclear, but may emerge as the molecular pathways control-
ling stumpy formation become better understood or the
molecular identity of SIF becomes known. This fascinating
area is currently unexplored, but the precedent from bacterial
intercellular communication systems provides evidence that
nuanced communication between different parasites circulat-
ing in the same host populations over considerable periods
of time will generate novel insights into the factors that con-
trol and optimize the infection dynamic of trypanosomes in
different mammalian hosts.
7. Therapeutic implications
Current drugs licensed to treat trypanosomiasis in humans and
livestock are old, have dangerous possible side effects, and
resistance is an increasing problem [82]. Consequently, many
initiatives to develop newdrugs for trypanosomiasis are under-
way. Most focus on killing the proliferative slender form of the
parasite in the bloodstream, but there is also the prospect oftargeting parasite development and transmission [83]. For
example, depletion of the TOR4 protein in trypanosomes
drives the parasites to generate stumpy-like forms in an irre-
versible arrest [52]. If induced pharmacologically, this would
leave affected parasites subject to clearance by the immune
system, as would the targeting of other kinases operating
on the same pathway [84]. Similarly, molecules that drive
stumpy formation could be activated pharmacologically to
achieve the same outcome, eliminating the parasite population
from the bloodstream [83,84]. In an extension of this approach,
inducing parasites to differentiate from bloodstream forms
to tsetse midgut procyclic forms in the host bloodstream
would render the parasites susceptible to rapid killing by the
alternative pathway of complement, as VSG loss is an early
component of the differentiation response in the tsetse
midgut. An example of this would be targeting the tyrosine
phosphatase TbPTP1 whose pharmacological inactivation has
been shown to initiate the differentiation of stumpy forms to
procyclic forms in the absence of any other external trigger
[85]. Likewise, a protein kinase with the same phenotype
when ablated byRNAi has also been identified [86]. An import-
ant caveat of this approach is that the pharmacological effect
must be 100% efficient; otherwise, there will be the potential
for the selection of parasites less able to arrest as stumpy
forms and sowith greater potential virulence [83]. Nonetheless,
as reduced stumpy formation could also reduce transmissibility
of any resistant parasites, this approachmight provide an inter-
esting evolution-resistant therapeutic approach that could
provide a useful complement or adjunct to newly developed
trypanocidal therapies.
8. Perspectives
The capacity of trypanosomes to undergo antigenic variation
and development to specialized transmission stages has long
been recognized. However, while the molecular mechanisms
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8underlying antigenic variation have been studied in detail over
many years, only recently have events been analysed in parasite
lines that exhibit full developmental competence. This rep-
resents an important step forward, as understanding the
interplay between antigenic variation and density-dependent
growth control in the mammalian bloodstream is necessary
for the dynamics of chronic trypanosome infections to be recog-
nized. These processes are likely to reveal a complex and
detailed picture of how the trypanosome sustains itself long-
term in mammalian hosts and ensures transmission. Moreover,
the interplay between these components has potentially import-
ant evolutionary implications likely to have impact on the
virulence, transmissibility and epidemiology of trypanosome
infections in the field. With the analysis of developmentally
competent lines, the identification of molecular components
necessary for the control of antigenic variation and develop-
mental progression in the bloodstream, and accessibility of a
wider range of field parasite strains (and genome sequences),
new insight is likely to emerge rapidly. These insights can be
exploited therapeutically or the insight used to understand
how therapeutic interventions might fail, or resistance develop.
Importantly, the general principles uncovered are also likely to
be broadly applicable among a range of related and unrelatedpathogens. The interplay between virulence and transmission
is complex but fundamental in pathogen biology. Trypano-
somes provide one of the most tractable models to understand
how this interaction operates, and the implications of perturb-
ing different components on the longevity and spread of the
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